Ken Griffin Akero Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$21.45 - $29.34 $368,940 - $504,648	-17,200 Reduced 36.6%	29,800 $854,000
Q2 2024 Aug 14, 2024	SELL	$18.31 - $24.62 $430,284 - $578,570	-23,500 Reduced 33.33%	47,000 $1.1 Million
Q1 2024 May 15, 2024	BUY	$17.76 - $31.18 $287,712 - $505,116	16,200 Added 29.83%	70,500 $1.78 Million
Q4 2023 Feb 14, 2024	BUY	$11.38 - $50.33 $37,554 - $166,089	3,300 Added 6.47%	54,300 $1.27 Million
Q3 2023 Nov 14, 2023	BUY	$41.19 - $52.25 $1.1 Million - $1.39 Million	26,600 Added 109.02%	51,000 $2.58 Million
Q2 2023 Aug 14, 2023	SELL	$36.89 - $56.88 $3,689 - $5,688	-100 Reduced 0.41%	24,400 $1.14 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $50.24 $857,210 - $1.16 Million	-23,000 Reduced 48.42%	24,500 $937,000
Q4 2022 Feb 14, 2023	SELL	$33.44 - $54.8 $2.44 Million - $4 Million	-73,000 Reduced 60.58%	47,500 $2.6 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $1.22 Million - $4.1 Million	120,500 New	120,500 $4.1 Million

190

73.8M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.33B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.